|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Gupta S, Kong W, Peng Y, Miao Q and
Mackillop WJ: Temporal trends in the incidence and survival of
cancers of the upper aerodigestive tract in Ontario and the United
States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weinstein IB: Cancer. Addiction to
oncogenes - the Achilles heal of cancer. Science. 297:63–64. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R,
Hammond EH, Fu KK and Milas L: Impact of epidermal growth factor
receptor expression on survival and pattern of relapse in patients
with advanced head and neck carcinoma. Cancer Res. 62:7350–7356.
2002.PubMed/NCBI
|
|
5
|
Rubin Grandis J, Melhem MF, Gooding WE,
Day R, Holst VA, Wagener MM, Drenning SD and Tweardy DJ: Levels of
TGF-α and EGFR protein in head and neck squamous cell carcinoma and
patient survival. J Natl Cancer Inst. 90:824–832. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vermorken JB, Mesia R, Rivera F, et al:
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanaka H, Nakashiro K, Iwamoto K, Tokuzen
N, Fujita Y, Shirakawa R, Oka R, Goda H and Hamakawa H: Targeting
Aurora kinase A suppresses the growth of human oral squamous cell
carcinoma cells in vitro and in vivo. Oral Oncol. 49:551–559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Furuta E, Okuda H, Kobayashi A and Watabe
K: Metabolic genes in cancer: Their roles in tumor progression and
clinical implications. Biochim Biophys Acta. 1805:141–152.
2010.PubMed/NCBI
|
|
10
|
Duxbury MS, Ito H, Zinner MJ, Ashley SW
and Whang EE: RNA interference targeting the M2 subunit of
ribonucleotide reductase enhances pancreatic adenocarcinoma
chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004.
View Article : Google Scholar
|
|
11
|
Eriksson S and Martin DW Jr:
Ribonucleotide reductase in cultured mouse lymphoma cells. Cell
cycle-dependent variation in the activity of subunit protein M2. J
Biol Chem. 256:9436–9440. 1981.PubMed/NCBI
|
|
12
|
Thelander M, Gräslund A and Thelander L:
Subunit M2 of mammalian ribonucleotide reductase. Characterization
of a homogeneous protein isolated from M2-overproducing mouse
cells. J Biol Chem. 260:2737–2741. 1985.PubMed/NCBI
|
|
13
|
Plunkett W, Huang P, Xu YZ, Heinemann V,
Grunewald R and Gandhi V: Gemcitabine: Metabolism, mechanisms of
action, and self-potentiation. Semin Oncol. 22(Suppl 11): 3–10.
1995.PubMed/NCBI
|
|
14
|
Aguilar-Ponce J, Granados-García M,
Villavicencio V, et al: Phase II trial of gemcitabine concurrent
with radiation for locally advanced squamous cell carcinoma of the
head and neck. Ann Oncol. 15:301–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Braakhuis BJM, van Dongen GAMS, Vermorken
JB and Snow GB: Preclinical in vivo activity of
2′,2′-difluorode-oxycytidine (Gemcitabine) against human head and
neck cancer. Cancer Res. 51:211–214. 1991.PubMed/NCBI
|
|
16
|
Senkal CE, Ponnusamy S, Rossi MJ, et al:
Potent antitumor activity of a novel cationic pyridinium-ceramide
alone or in combination with gemcitabine against human head and
neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp
Ther. 317:1188–1199. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saddoughi SA, Garrett-Mayer E, Chaudhary
U, et al: Results of a phase II trial of gemcitabine plus
doxorubicin in patients with recurrent head and neck cancers: Serum
C18-ceramide as a novel biomarker for monitoring
response. Clin Cancer Res. 17:6097–6105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fury MG, Haque S, Stambuk H, Shen R,
Carlson D and Pfister D: A phase 2 study of pemetrexed plus
gemcitabine every 2 weeks for patients with recurrent or metastatic
head and neck squamous cell cancer. Cancer. 117:795–801. 2011.
View Article : Google Scholar
|
|
19
|
van Herpen CML, Locati LD, Buter J, et al:
Phase II study on gemcitabine in recurrent and/or metastatic
adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J
Cancer. 44:2542–2545. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shintani S, Mihara M, Nakahara Y, Aida T,
Tachikawa T and Hamakawa H: Lymph node metastasis of oral cancer
visualized in live tissue by green fluorescent protein expression.
Oral Oncol. 38:664–669. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shintani S, Hamakawa H, Nakashiro K,
Shirota T, Hatori M, Tanaka M, Kuroshita Y and Kurokawa Y: Friend
leukaemia insertion (Fli)-1 is a prediction marker candidate for
radiotherapy resistant oral squamous cell carcinoma. Int J Oral
Maxillofac Surg. 39:1115–1119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kobayashi H, Higashiyama M, Minamigawa K,
Tanisaka K, Takano T, Yokouchi H, Kodama K and Hata T: Examination
of in vitro chemosensitivity test using collagen gel droplet
culture method with colorimetric endpoint quantification. Jpn J
Cancer Res. 92:203–210. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Higashiyama M, Oda K, Okami J, Maeda J,
Kodama K, Imamura F, Minamikawa K, Takano T and Kobayashi H:
Prediction of chemotherapeutic effect on postoperative recurrence
by in vitro anticancer drug sensitivity testing in non-small cell
lung cancer patients. Lung Cancer. 68:472–477. 2010. View Article : Google Scholar
|
|
24
|
Souglakos J, Boukovinas I, Taron M, et al:
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels
and clinical outcome of lung adenocarcinoma patients treated with
docetaxel/gemcitabine. Br J Cancer. 98:1710–1715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morikawa T, Maeda D, Kume H, Homma Y and
Fukayama M: Ribonucleotide reductase M2 subunit is a novel
diagnostic marker and a potential therapeutic target in bladder
cancer. Histopathology. 57:885–892. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rahman MA, Amin ARMR, Wang D, et al: RRM2
regulates Bcl-2 in head and neck and lung cancers: A potential
target for cancer therapy. Clin Cancer Res. 19:3416–3428. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan H, Villegas C and Wright JA:
Ribonucleotide reductase R2 component is a novel malignancy
determinant that cooperates with activated oncogenes to determine
transformation and malignant potential. Proc Natl Acad Sci USA.
93:14036–14040. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rahman MA, Amin ARMR, Wang X, et al:
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses
head and neck tumor growth. J Control Release. 159:384–392. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shao J, Zhou B, Chu B and Yen Y:
Ribonucleotide reductase inhibitors and future drug design. Curr
Cancer Drug Targets. 6:409–431. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wadler S, Makower D, Clairmont C, Lambert
P, Fehn K and Sznol M: Phase I and pharmacokinetic study of the
ribonucleotide reductase inhibitor,
3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by
96-hour intravenous continuous infusion. J Clin Oncol.
22:1553–1563. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Desai AA, Schilsky RL, Young A, Janisch L,
Stadler WM, Vogelzang NJ, Cadden S, Wright JA and Ratain MJ: A
phase I study of antisense oligonucleotide GTI-2040 given by
continuous intravenous infusion in patients with advanced solid
tumors. Ann Oncol. 16:958–965. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yabushita H, Ohnishi M, Komiyama M, Mori T
and Noguchi M, Kishida T, Noguchi Y, Sawaguchi K and Noguchi M:
Usefulness of collagen gel droplet embedded culture drug
sensitivity testing in ovarian cancer. Oncol Rep. 12:307–311.
2004.PubMed/NCBI
|
|
33
|
Mori S, Kunieda K, Sugiyama Y and Saji S:
Prediction of 5-fluorouracil and cisplatin synergism for advanced
gastrointestinal cancers using a collagen gel droplet embedded
culture. Surg Today. 33:577–583. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mekata E, Sonoda H, Shimizu T, Tatsuta T,
Yamaguchi T, Endo Y and Tani T: Clinical predictive value of in
vitro anti-cancer drug sensitivity test for the therapeutic effect
of adjuvant chemotherapy in patients with stage II–III colorectal
cancer. Mol Clin Oncol. 1:763–767. 2013.
|
|
35
|
Zhang ZP, Sun YL, Fu L, Gu F, Zhang L and
Hao XS: Correlation of Notch1 expression and activation to
cisplatin-sensitivity of head and neck squamous cell carcinoma. Ai
Zheng. 28:100–103. 2009.PubMed/NCBI
|
|
36
|
Itoi T, Sofuni A, Fukushima N, Itokawa F,
Tsuchiya T, Kurihara T, Moriyasu F, Tsuchida A and Kasuya K:
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment
biopsies obtained from unresectable pancreatic carcinomas. J
Gastroenterol. 42:389–394. 2007. View Article : Google Scholar : PubMed/NCBI
|
